“Band aid for the heart“ generated from stem cells starts first clinical trial worldwide
Embargo: Tuesday, February 09, 2021, 3:50 pm
INVITATION TO PRESS BRIEFING: Tuesday, February 09, 2021, 2:30 pm, participation via live stream. Please register.
First in human application: The clinical trial will investigate the application of myocardial tissue generated from stem cells in patients with severe heart failure in order to improve pumping function significantly
(umg/dzhk) 60 million people suffer from heart failure worldwide. In Germany, 4 million people are affected. Heart failure is the most common reason for hospitali-zation with 500,000 cases annually. Now for the first time, the Paul-Ehrlich-Institute approved a clinical trial with a myocardial compound generated from stem cells, a so-called “band aid for the heart”. The clinical trial BioVAT-HF-DZHK20 “Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure” is currently being initiated at the heart center of the University Medical Center Göttingen (UMG). The novel biological therapy approach is being administered to patients for the first time worldwide and was developed at the Göttingen site of the German Center for Cardiovascular Research (DZHK).
We would like to inform you about the start of the trial, the idea, the application and the further options and we cordially invite you to a
PRESS BRIEFING (virtual)
“Band aid for the heart” generated from stem cells to repair the heart muscle in case of heart failure starts first clinical trial worldwide
February 09, 2021, 2:30 pm
Meeting-ID: 961 2515 8108; Conference code: 549844
Please treat the dial-in information as confidential and do not share them with third parties. Please indicate your name upon login.
Quick dial-in mobile
Dial-in according to location
+49 30 5679 5800 Germany
+49 69 3807 9883 Germany
+49 695 050 2596 Germany
+49 69 7104 9922 Germany
Meeting-ID: 961 2515 8108
Conference code: 549844
Search for local number: https://uni-goettingen.zoom.us/u/abVcMrHNR
Please address your questions, stating your name and the publication you work for, to firstname.lastname@example.org or use the chat function of the Zoom meeting. NOTE: The press meeting will be recorded.
We ask you to register briefly for your participation in order for us to get an overview of the virtual number of participants under email@example.com, Phone 0551/39 61022 or 0551/39-61020.
YOUR CONVERSATION PARTNERS:
• Björn Thümler, Secretary for Science and Culture in Lower Saxony
• Prof. Dr. Wolfgang Brück, Spokesperson of the University Medical Center Göttingen
• Prof. Dr. Wolfram-Hubertus Zimmermann, Scientific Principal Investigator of the “Band aid for the heart” trial,
Director of the Institute of Pharmacology and Toxicology of UMG
• Prof. Dr. Gerd Hasenfuß, Chairman of the Heart Center at the University Medicine Göttin-gen
• Prof. Dr. Ingo Kutschka, Director of the Department for Thoracic, Cardiac and Vascular Surgery at UMG
• Prof. Dr. Tim Seidler, Lead of the clinical trial,
Deputy Director of the Department for Cardiology and Pneumology at UMG
• Dr. Ahmad-Fawad Jebran, deputy lead of the clinical trial,
Attending Physician of the Department for Thoracic, Cardiac and Vascular Surgery at UMG
• Associate Professor. Dr. Joachim Riggert, Head of the Central Department for Transfusion Medicine at UMG
Universitätsmedizin Göttingen, Georg-August-Universität
Unternehmenskommunikation, Presse- und Öffentlichkeitsarbeit
Stefan Weller, Phone +49 551 39-61020
Von-Siebold-Str. 3, 37075 Göttingen